Inverse psoriasiform eruption during pembrolizumab therapy for metastatic melanoma

JAMA Dermatology

Volumn 152, Issue 5, 2016, Pages 590-592

  Totonchy, Mariam B ^a   Ezaldein, Harib H ^a   Ko, Christine J ^a   Choi, Jennifer N ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; MONOCLONAL ANTIBODY;

ADVANCED CANCER; BACTERIUM CULTURE; CASE REPORT; CELLULITIS; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREGULATION; INFLAMMATORY INFILTRATE; INNATE IMMUNITY; LETTER; LEUKOCYTOSIS; LUNG METASTASIS; LYMPHOCYTIC INFILTRATION; METASTATIC MELANOMA; MULTIPLE CYCLE TREATMENT; NECROTIZING FASCIITIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PSORIASIS; QUALITY OF LIFE; RASH; SKIN BIOPSY; SPINE METASTASIS; SURVIVAL RATE; SURVIVAL TIME; BIOPSY; CHEMICALLY INDUCED; DIFFERENTIAL DIAGNOSIS; DRUG EFFECTS; DRUG ERUPTION; FEMALE; GYNECOLOGIC DISEASE; LUNG TUMOR; MELANOMA; PATHOLOGY; SECONDARY; SKIN; SKIN TUMOR; SPINE TUMOR; STAPHYLOCOCCUS INFECTION; VERY ELDERLY;

AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOPSY; DIAGNOSIS, DIFFERENTIAL; DRUG ERUPTIONS; FEMALE; GENITAL DISEASES, FEMALE; HUMANS; LUNG NEOPLASMS; MELANOMA; PSORIASIS; SKIN; SKIN NEOPLASMS; SPINAL NEOPLASMS; STAPHYLOCOCCAL INFECTIONS;

EID: 84969242580     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2015.5210     Document Type: Letter

References (6)

1. Merelli B, Massi D, Cattaneo L, Mandalà M. Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities. Crit Rev Oncol Hematol. 2014;89(1):140-165.
2. Robert C, Schachter J, Long GV, et al; KEYNOTE-006 investigators. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015; 372(26):2521-2532.
3. Sanlorenzo M, Vujic I, Daud A, et al. Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol. 2015;151 (11):1206-1212.
4. Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32(10):1020-1030.
5. Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384 (9948):1109-1117.
6. Shoushtari AN, Postow MA, Horvat TZ, Adel NG, Dang T, Chapman PB. Safety of pembrolizumab (pem) in patients (pts) who stopped ipilimumab (ipi) due to immune-related adverse events. Presented at the ASCO Annual Meeting; May 29 to June 2, 2015; Chicago, IL.